Stefano Dastoli

Catanzaro, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Clinical profile, patient experience, and management of vitiligo in Italy: Data from the National 2024 Vitiligo Week Awareness Campaign.

Clinical profile, patient experience, and management of vitiligo in Italy: Data from the National 2024 Vitiligo Week Awareness Campaign.

Journal: JAAD international

Published: August 01, 2026

Not all scabies come with a… burrow.

Not all scabies come with a… burrow.

Journal: Dermatology reports

Published: March 07, 2025

Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study.

Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study.

Journal: Clinical and experimental dermatology

Published: October 11, 2024

Early intervention and cumulative life course impairment in psoriasis: a review.

Early intervention and cumulative life course impairment in psoriasis: a review.

Journal: Clinical and experimental dermatology

Published: May 05, 2024

Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations.

Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations.

Journal: Journal of asthma and allergy

Published: April 18, 2024

Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients.

Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients.

Journal: Clinical and experimental dermatology

Published: March 30, 2024

Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis.

Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis.

Journal: Journal of clinical medicine

Published: November 24, 2023

Safety of omalizumab in chronic urticaria during pregnancy: a real-life study.

Safety of omalizumab in chronic urticaria during pregnancy: a real-life study.

Journal: Clinical and experimental dermatology

Published: October 05, 2023

Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.

Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.

Journal: Clinical, cosmetic and investigational dermatology

Published: May 16, 2023

Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.

Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.

Journal: The Journal of dermatological treatment

Published: April 07, 2023

Skin swab detects proteomic changes in non-lesional skin of adults with atopic dermatitis treated with dupilumab.

Skin swab detects proteomic changes in non-lesional skin of adults with atopic dermatitis treated with dupilumab.

Journal: Italian journal of dermatology and venereology

Published: June 06, 2022

Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicenter study.

Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: a multicenter study.

Journal: The Journal of dermatological treatment

Published: April 18, 2022

Showing 1-12 of 49

Last Updated: 09/26/2026